计算溶液所需的质量、体积或浓度。
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,干燥。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).
In Vivo
Mavodelpar (10 mg/kg; i.p., once daily, from 6 to 17 weeks of age) effectively suppresses glomerular injury and renal fibrosis, and decreases levels of fibrosis-related proteins . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male and female B6129SF1-Col4a3 -/- mice Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg, once daily, from 6 to 17 weeks of age Result: Suppressed proteinuria and blood urea nitrogen (BUN) levels. Reduced glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. Decreased the expression level of the activated fibroblast marker alpha-SMA and Collagen I and IV.
Form:Solid